Natpar

Natpar Uses, Dosage, Side Effects, Food Interaction and all others data.

Natpar (PTH) is a single-chain polypeptide composed of 84 amino acids. Available as Preotact, it is an identical form of human recombinant hormome which produced as a fusion protein undergoeing post-translational processing involving the cleavage of the OmpA leader sequence, leaving the mature protein as a single-chain 84 amino-acids polypeptide (9.4 kDa).

Preotact is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures and is marketed in Europe by Nycomed. Preos is a registered trade mark owned by NPS Pharmaceuticals, Inc. The name Preos and the New Drug Application is pending approval by the U.S. Food and Drug Administration (FDA).

Natpar is responsible for the fine regulation of serum calcium concentration on a minute-to-minute basis. This is achieved by the acute effects of the hormone on calcium resorption in bone and calcium reabsorption in the kidney. The phosphate mobilized from bone is excreted into the urine by means of the hormone's influence on renal phosphate handling. Natpar also stimulates calcium absorption in the intestine, this being mediated indirectly by 1,25-dihydroxyvitamin D. Thus, a hypocalcemic stimulus of parathyroid hormone secretion results in an increased influx of calcium from three sources (bone, kidney, and intestine), resulting in a normalization of the serum calcium concentration without change in the serum phosphate concentration.

Trade Name Natpar
Generic Parathyroid hormone
Parathyroid hormone Other Names Parathormone, Parathormone (human recombinant), Parathyrin, Parathyroid hormone, PTH
Type Injection
Formula C408H674N126O126S2
Weight 9420.0 Da
Groups Approved, Investigational
Therapeutic Class
Manufacturer Shire Pharmaceuticals Limited
Available Country United Kingdom
Last Updated: September 19, 2023 at 7:00 am
Natpar
Natpar

Uses

Natpar is an analog of human parathyroid hormone (PTH) used to treat hypocalcemia caused by hypoparathyroidism.

For use/treatment in osteoporosis.

Natpar is also used to associated treatment for these conditions: Hypocalcemia, Hypoparathyroidism

How Natpar works

The biological actions of rhPTH are mediated through binding to at least two distinct high- affinity cell-surface receptors specific for the N-terminal and C-terminal regions of the molecule, both of which are required for normal bone metabolism. The N-terminal portion of the molecule is primarily responsible for the bone building effects of parathyroid hormone. The C-terminal portion of the molecule has antiresorptive activity and is necessary for normal regulation of N-terminal fragment activity.

Food Interaction

No interactions found.

Volume of Distribution

The volume of distribution at steady-state following intravenous administration is approximately 5.4 liters with an interpatient variability of about 40%.

Elimination Route

The absolute bioavailability after subcutaneous administration in the abdomen is 55% for doses of 100 micrograms.

Half Life

1.5 hours.

Elimination Route

Carboxy-terminal fragments are filtered by the kidney and subsequently broken down into even smaller fragments during tubular reuptake.

Innovators Monograph

You find simplified version here Natpar

*** Taking medicines without doctor's advice can cause long-term problems.
Share